Zoetis (ZTS)
(Delayed Data from NYSE)
$192.64 USD
-0.60 (-0.31%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $192.69 +0.05 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$192.64 USD
-0.60 (-0.31%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $192.69 +0.05 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum F VGM
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
Is Trending Stock Zoetis Inc. (ZTS) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Zoetis (ZTS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 2.99% and 2.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling Zoetis (ZTS) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
Wall Street Analysts Look Bullish on Zoetis (ZTS): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Zoetis (ZTS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the latest trading session, Zoetis (ZTS) closed at $145.54, marking a -0.66% move from the previous day.
Zoetis (ZTS) Stock Moves -0.14%: What You Should Know
by Zacks Equity Research
In the latest trading session, Zoetis (ZTS) closed at $149.77, marking a -0.14% move from the previous day.
Company News for Apr 15, 2024
by Zacks Equity Research
Companies In The Article Are:INTC,ZTS,X,NPSCY and PGR
Why Zoetis (ZTS) Dipped More Than Broader Market Today
by Zacks Equity Research
The latest trading day saw Zoetis (ZTS) settling at $165.69, representing a -0.1% change from its previous close.
Zoetis (ZTS) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Company News for Feb 14, 2024
by Zacks Equity Research
Companies in The News Are: ZTS,MAR,ECL,HAS
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH